Results 31 to 40 of about 170,023 (183)

Interferon beta-1a in chronic inflammatory demyelinating polyneuropathy: case report Interferon beta en polineuropatía crónica inflamatoria desmienlinizante: caso clínico

Arquivos de Neuro-Psiquiatria, 2004
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated neuropathy. It presents with a course of progression which may be slow and steady or step-wise or relapsing.
Andrés Maria Villa, Orlando Garcea, Marianna Di Egidio, Roberto Saizar, Roberto Eduardo Pedro Sica   +4 more
doaj   +1 more source

Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review

Journal of Community Hospital Internal Medicine Perspectives, 2021
Type 1 interferons, especially interferon-beta, has been reported to be effective in COVID-19 patients in multiple randomized controlled trials. The aim of our meta-analysis and systematic review is to assess efficacy of subcutaneous IFN-beta in regards ...
Abuzar A. Asif, Habiba Hussain, Sriviji Senthil Kumaran, Salman B. Syed, Varun Vanka, Manisha Tharoor, Umme Salma Rangwala, Urvashi Rathore, Malay Singhal, Tulika Chatterjee   +9 more
doaj   +1 more source

Improvement of Interferon-Beta Production in Transient Expression System of CHO DG44 by a Codon Bias Change in Instability Sequence (CRID) of C-terminal of Interferon Beta Gene

مجله دانشکده پزشکی اصفهان, 2012
Background: Improvement of mRNA stability and therefore, production of interferon beta (IFNb) in Chinese hamster ovary (CHO) cell, as a recombinant protein expression system, is very important.
Zahra Bezi, Hassan Korbekandi, Batool Hashemibeni, Zohreh Hojjati, Amin Moradi Hassanabad, Mohammad Reza Marasi   +5 more
doaj  

Successful treatment of plasmapheresis followed by interferon beta-1a in a child with severe COVID-19

Journal of Research in Medical Sciences, 2021
COVID-19 outbreak has become a global health concern due to challenges in treatment and high mortality rate; therefore, its therapeutic approaches play an important role in reducing the mortality rate and resolving this concern.
Rana Saleh, Hamid Rahimi, Amin Dehghan, Atefeh Sadeghizadeh, Alaleh Gheisari, Shima Saeidi, Zahra Pourmoghaddas   +6 more
doaj   +1 more source

Analysis of Association Between Genetic Heterogeneity of Interferon Beta Receptor Promoter and Therapeutic Response to Interferon-beta in a Patient with Multiple Sclerosis [PDF]

, 2021
Samin Hajian, Mehrdokht Mazdeh, Fatemeh Nouri, Meysam Soleimani   +3 more
openalex   +1 more source

USE OF INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH MULTIPLE SCLEROSIS: EFFICACY, SAFETY AND ADHERENCE TO THERAPY

Педиатрическая фармакология, 2009
Immunomodulatory drugs reduce relapse rate and disease progression in relapsing-remitting multiple sclerosis but extensive data are not available on the effectiveness and tolerability of these drugs in childhood or adolescence.
O.V. Bykova, T.V. Sidorenko, A.N. Platonova, N.V. Gol’tsova, L.M. Kuzenkova, A.N. Boiko   +5 more
doaj   +2 more sources

Thrombotic microangiopathy associated with use of interferon-beta

International Journal of Nephrology and Renovascular Disease, 2012
Teresa Olea,1 Raquel Díaz-Mancebo,1 Maria-Luz Picazo,2 Jorge Martínez-Ara,1 Angel Robles,3 Rafael Selgas,11Departments of Nephrology, 2Pathology, 3Internal Medicine, Hospital Universitario La Paz, Madrid, SpainAbstract: Interferon ...
Robles A, Martinez-Ara J, Picazo ML, Diaz-Mancebo R, Olea T, Selgas R   +5 more
doaj  

Interferon-beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription [PDF]

Acta Medica Iranica, 2012
None of the approved immunomodulatory drugs in adults Multiple Sclerosis (MS) patients have been officially approved for the pediatric patients and are currently used off-label in this population.
Keivan Basiri, Masood Etemadifar, Fatemeh Derakhshan, Fereshteh Ashtari, Vahid Shaygannejad, Zahra Fatehi, Amir Hadi Maghzi, Farzad Fatehi   +7 more
doaj   +1 more source

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis

Therapeutic Advances in Neurological Disorders, 2010
Background: Mycophenolate mofetil (MMF, CellCept ® ) has been utilized as an antirejection agent in transplant recipients and in patients with myriad autoimmune disorders including multiple sclerosis (MS).
Elliot M. Frohman, Gary Cutter, Gina Remington, Hongjiang Gao, Howard Rossman, Bianca Weinstock-Guttman, Jacqueline E. Durfee, Amy Conger, Ellen Carl, Katherine Treadaway, Eric Lindzen, Amber Salter, Teresa C. Frohman, Anjali Shah, Angela Bates, Jennifer L. Cox, Michael G. Dwyer, Olaf Stuve, Benjamin M. Greenberg, Michael K. Racke, Robert Zivadinov   +20 more
doaj   +1 more source

Interferon Beta-secreting Mesenchymal Stem Cells [PDF]

, 2020
National Cancer Institute
openalex   +1 more source